JPRN-UMIN000016346招募中2 期
Dexamethasone, ifosfamide, carboplatin, and etoposide in treating patients with refractory lymphoblastic lymphoma. - DexICE therapy for refractory LB
Japan children's cancer group.0 个研究点目标入组 24 人开始时间: 2015年2月14日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1years-old 至 19years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Down syndrome. 2) Existence of CNS infiltration. 3) Philadelphia chromosome positive disease. 4) Myelodysplastic syndromes. 5) Other previous illness of malignant tumor. 6) Previous therapy of organ transplantation including blood stem cells. 7) Previous illness of congenital and HIV related immunodeficiency. 8) Additional status that a doctor in charge judges to be improper.
研究者
相似试验
进行中（未招募）
1 期
Daratumumab, pomalidomide and dexamethasone for del(17p) positive relapsed and relapsed/refractory multiple myeloma patients [DEDALO]Multiple Myeloma patients with relapsed or relapsed/refractory disease with the presence of del(17p) in the plasma cell cloneMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2018-002090-21-ITFondazione EMN Italy Onlus45
进行中（未招募）
1 期
A Trial for relapsed and relapsed/refractory multiple myeloma patientsMultiple Myeloma relapsed and/or refractoryMedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104CTIS2023-506733-30-00Fondazione European Myeloma Network Italy O.N.L.U.S.45
已完成
3 期
MEtoclopramide, DExamethasone or Aloxi (palonosetron) for the prevention of delayed chemotherapy-induced nausea and vomiting in moderately emetogenic non-AC-based chemotherapy: the MEDEA trialalle vormen van solide tumorenchemotherapy induced nausea and vomitingnausea and vomiting caused by chemotherapyNL-OMON44716Vrije Universiteit Medisch Centrum450
招募中
不适用
Aprepitant, Palonosetron and Dexamethasone Antiemetic Therapy Evaluation trial in germ cell tumor (APDATE)Germ cell tumorJPRN-UMIN000008110Department of Urology, Sapporo Medical University School of Medicine30
已完成
2 期
Bortezomib, cyclophosphamide plusd dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myelomaJPRN-UMIN000009765Kanagawa Cancer Center30